<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Until recently <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">peritoneal carcinomatosis</z:e> (PC) arising from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) was considered to be a <z:e sem="disease" ids="C0679247" disease_type="Disease or Syndrome" abbrv="">terminal disease</z:e> manifestation </plain></SENT>
<SENT sid="1" pm="."><plain>Despite palliative systemic chemotherapy (CHT) the majority of patients died within a few months </plain></SENT>
<SENT sid="2" pm="."><plain>Nowadays cytoreductive surgery (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e>) of the peritoneal cavity in combination with hyperthermic intraperitoneal CHT and perioperative systemic CHT may offer a chance for long-term survival in selected groups of patients </plain></SENT>
<SENT sid="3" pm="."><plain>In this study we report the results obtained with this treatment strategy in 30 consecutive patients </plain></SENT>
<SENT sid="4" pm="."><plain>Data were assessed prospectively </plain></SENT>
<SENT sid="5" pm="."><plain>After a median follow-up of 16.9 months the median survival time in <z:hpo ids='HP_0000001'>all</z:hpo> 30 patients reached 24.3 months </plain></SENT>
<SENT sid="6" pm="."><plain>Favorable prognostic factors are a low extent of intraperitoneal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> as characterized by a low <z:e sem="disease" ids="C0153467" disease_type="Neoplastic Process" abbrv="">peritoneal cancer</z:e> index (median survival PCI ≤ 10: 33.2 months vs. PCI 11-19: 12.1 months) and a complete or nearly complete <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> (median survival CCR 0/1: 33.1 months vs. CCR2/3: 12.1 months) </plain></SENT>
<SENT sid="7" pm="."><plain>The 2-year overall survival was 89% for patients with a PCI ≤ 10 and 65% for those with surgical CCR 0/1 cytoreduction </plain></SENT>
<SENT sid="8" pm="."><plain>As not every patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and PC may profit from this relatively aggressive therapy an interdisciplinary patient selection (<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> board) and treatment in experienced surgical <z:hpo ids='HP_0002664'>oncology</z:hpo> centers is recommended </plain></SENT>
</text></document>